InsiderTrades.com logo
$2 Trillion Disappears Because of Fed's Secretive New Move
From Stansberry Research   |   Ad
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Click here to see his new research now.

DMAC Insider Trading

Insider Ownership Percentage: 7.20%
Insider Buying (Last 12 Months): $3,000,000.00
Insider Selling (Last 12 Months): $0.00

DiaMedica Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at DiaMedica Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DiaMedica Therapeutics Share Price & Price History

Current Price: $6.41
Price Change: ▲ Price Increase of +1.54 (31.62%)
As of 12/20/2024 06:40 PM ET

This chart shows the closing price history over time for DMAC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research   |   Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.

DiaMedica Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/28/2024Koch Thomas VonMajor ShareholderBuy1,200,000$2.50$3,000,000.005,526,435View SEC Filing Icon  
6/23/2023David J WambekeInsiderBuy38,364$3.91$150,003.24507,114View SEC Filing Icon  
6/23/2023Dietrich John PaulsCEOBuy12,787$3.91$49,997.1768,591View SEC Filing Icon  
6/23/2023Koch Thomas VonMajor ShareholderBuy1,470,588$3.40$4,999,999.204,326,435View SEC Filing Icon  
6/23/2023Randall Michael GiuffreDirectorBuy65,000$3.91$254,150.00360,355View SEC Filing Icon  
6/23/2023Scott KellenCFOBuy10,000$3.91$39,100.0032,290View SEC Filing Icon  
4/10/2023David J WambekeInsiderBuy468,750$1.60$750,000.00468,750View SEC Filing Icon  
12/8/2022Randall Michael GiuffreDirectorBuy20,000$1.40$28,000.00223,146View SEC Filing Icon  
12/6/2022Randall Michael GiuffreDirectorBuy2,300$1.35$3,105.00180,572View SEC Filing Icon  
12/1/2022Randall Michael GiuffreDirectorBuy46,133$1.20$55,359.60177,453View SEC Filing Icon  
11/29/2022Randall Michael GiuffreDirectorBuy18,125$1.19$21,568.75128,350View SEC Filing Icon  
11/16/2022Dietrich John PaulsCEOBuy20,000$1.21$24,200.0055,804View SEC Filing Icon  
7/8/2022Koch Thomas VonMajor ShareholderBuy207,974$1.33$276,605.422,855,827View SEC Filing Icon  
See Full Table
Wall Street Icon: “You must get on the right side of this thing”
From InvestorPlace   |   Ad
I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.
This market shakeup is going to be much more intense.

SEC Filings (Institutional Ownership Changes) for DiaMedica Therapeutics (NASDAQ:DMAC)

10.12% of DiaMedica Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DMAC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

DiaMedica Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024Geode Capital Management LLC306,958$1.29M0.0%+29.6%0.718%Search for SEC Filing on Google Icon
11/15/2024Point72 Asia Singapore Pte. Ltd.9,498$40K0.0%N/A0.022%Search for SEC Filing on Google Icon
10/18/2024Blue Trust Inc.44,247$0.19M0.0%N/A0.104%Search for SEC Filing on Google Icon
8/16/2024Magnolia Capital Advisors LLC29,500$87K0.0%N/A0.069%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.1,013,522$2.81M0.0%+26.3%2.670%Search for SEC Filing on Google Icon
2/15/2024Paragon Associates & Paragon Associates II Joint Venture500,000$1.42M3.3%+6.4%1.318%Search for SEC Filing on Google Icon
2/7/2024Avantax Advisory Services Inc.12,500$36K0.0%N/A0.033%Search for SEC Filing on Google Icon
11/15/2023Stonebridge Capital Advisors LLC20,000$52K0.0%N/A0.053%Search for SEC Filing on Google Icon
11/13/2023EAM Investors LLC212,512$0.55M0.1%-21.4%0.560%Search for SEC Filing on Google Icon
11/9/2023Bleichroeder LP222,317$0.57M0.1%-24.4%0.586%Search for SEC Filing on Google Icon
11/1/2023Jacob Asset Management of New York LLC168,730$0.44M0.6%-15.1%0.445%Search for SEC Filing on Google Icon
8/30/2023Cooperman Leon G875,993$3.78M0.2%+0.9%2.308%Search for SEC Filing on Google Icon
8/10/2023Jacob Asset Management of New York LLC198,730$0.86M1.0%-15.0%0.738%Search for SEC Filing on Google Icon
8/2/2023Catalyst Financial Partners LLC36,267$0.16M0.1%+44.4%0.135%Search for SEC Filing on Google Icon
4/11/2023Catalyst Financial Partners LLC25,110$38K0.0%+73.5%0.095%Search for SEC Filing on Google Icon
5/12/2022Jacob Asset Management of New York LLC265,000$0.66M0.4%-3.6%1.002%Search for SEC Filing on Google Icon
2/15/2022Stonepine Capital Management LLC1,194,670$4.46M2.0%+620.7%4.519%Search for SEC Filing on Google Icon
11/15/2021Marshall Wace LLP10,031$40K0.0%-93.6%0.053%Search for SEC Filing on Google Icon
11/15/2021Manatuck Hill Partners LLC273,100$1.10M0.4%-52.1%1.454%Search for SEC Filing on Google Icon
11/12/2021Stonepine Capital Management LLC165,775$0.67M0.3%-60.5%0.882%Search for SEC Filing on Google Icon
11/12/2021Jump Financial LLC18,300$73K0.0%N/A0.097%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.55,970$0.23M0.0%-8.6%0.298%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace LLP155,662$0.69M0.0%+104.9%0.829%Search for SEC Filing on Google Icon
8/16/2021State Street Corp30,217$0.13M0.0%N/A0.161%Search for SEC Filing on Google Icon
8/16/2021Corriente Advisors LLC203,641$0.91M0.5%-76.6%1.084%Search for SEC Filing on Google Icon
8/16/2021Marshall Wace LLP155,662$0.69M0.0%+104.9%0.829%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC94,100$0.42M0.0%-38.5%0.501%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC133,569$0.59M0.0%+4.0%0.711%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.786,266$3.50M0.0%-7.1%4.185%Search for SEC Filing on Google Icon
8/12/2021Trexquant Investment LP17,019$76K0.0%N/A0.091%Search for SEC Filing on Google Icon
8/12/2021Dimensional Fund Advisors LP14,074$63K0.0%N/A0.075%Search for SEC Filing on Google Icon
8/12/2021JPMorgan Chase & Co.8,299$37K0.0%N/A0.044%Search for SEC Filing on Google Icon
8/12/2021Bank of Montreal Can142,846$0.69M0.0%+36.7%0.760%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC20,601$0.19M0.0%N/A0.110%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC35,536$0.33M0.0%N/A0.189%Search for SEC Filing on Google Icon
5/18/2021Millennium Management LLC70,281$0.64M0.0%+72.0%0.374%Search for SEC Filing on Google Icon
5/18/2021Point72 Asset Management L.P.552,250$5.05M0.0%-31.0%2.940%Search for SEC Filing on Google Icon
5/18/2021Corriente Advisors LLC870,228$7.96M2.9%+7.8%4.632%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC20,601$0.19M0.0%N/A0.110%Search for SEC Filing on Google Icon
5/13/2021Barclays PLC3,412$31K0.0%N/A0.018%Search for SEC Filing on Google Icon
5/13/2021Renaissance Technologies LLC153,100$1.40M0.0%+35.0%0.815%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp40,576$0.37M0.0%-5.4%0.216%Search for SEC Filing on Google Icon
5/13/2021Bank of Montreal Can104,524$0.98M0.0%+27.7%0.556%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp85,026$0.78M0.0%-29.7%0.453%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC128,468$1.18M0.0%+23.9%0.684%Search for SEC Filing on Google Icon
5/12/2021Granite Point Capital Management L.P.184,380$1.69M0.1%-66.3%0.981%Search for SEC Filing on Google Icon
5/11/2021EAM Investors LLC108,232$0.99M0.1%-1.6%0.576%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.60,165$0.55M0.0%+7.9%0.320%Search for SEC Filing on Google Icon
4/27/2021Dorsey Wright & Associates3,937$36K0.4%N/A0.021%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC15,712$0.16M0.0%N/A0.084%Search for SEC Filing on Google Icon
2/17/2021Jane Street Group LLC12,537$0.13M0.0%N/A0.067%Search for SEC Filing on Google Icon
2/16/2021ExodusPoint Capital Management LP13,160$0.13M0.0%N/A0.070%Search for SEC Filing on Google Icon
2/12/2021Stonepine Capital Management LLC950,000$9.63M7.4%-17.1%5.070%Search for SEC Filing on Google Icon
2/11/2021Northern Trust Corp120,989$1.23M0.0%+3.6%0.646%Search for SEC Filing on Google Icon
2/11/2021Valeo Financial Advisors LLC5,000$51K0.0%N/A0.027%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC113,400$1.15M0.0%+18.1%0.605%Search for SEC Filing on Google Icon
2/9/2021Bank of New York Mellon Corp42,905$0.44M0.0%+218.5%0.229%Search for SEC Filing on Google Icon
2/6/2021Granite Point Capital Management L.P.546,855$5.55M0.3%-15.5%2.918%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.55,781$0.57M0.0%+27.4%0.298%Search for SEC Filing on Google Icon
11/13/2020Morgan Stanley9,100$38K0.0%+56.9%0.049%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
DiaMedica Therapeutics logo
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More on DiaMedica Therapeutics

Today's Range

Now: $6.41
Low: $4.75
High: $6.41

50 Day Range

MA: $4.71
Low: $4.01
High: $6.41

52 Week Range

Now: $6.41
Low: $2.14
High: $6.41

Volume

248,377 shs

Average Volume

59,785 shs

Market Capitalization

$274.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Who are the company insiders with the largest holdings of DiaMedica Therapeutics?

DiaMedica Therapeutics' top insider shareholders include:
  1. Koch Thomas Von (Major Shareholder)
  2. David J Wambeke (Insider)
  3. Randall Michael Giuffre (Director)
  4. Dietrich John Pauls (CEO)
  5. Scott Kellen (CFO)
Learn More about top insider investors at DiaMedica Therapeutics.

Who are the major institutional investors of DiaMedica Therapeutics?

DiaMedica Therapeutics' top institutional investors include:
  1. Geode Capital Management LLC — 0.72%
  2. Blue Trust Inc. — 0.10%
  3. Point72 Asia Singapore Pte. Ltd. — 0.02%
Learn More about top institutional investors of DiaMedica Therapeutics stock.

Which institutional investors are buying DiaMedica Therapeutics stock?

Within the last quarter, DMAC stock was bought by institutional investors including:
  1. Geode Capital Management LLC
  2. Blue Trust Inc.
  3. Point72 Asia Singapore Pte. Ltd.
Within the previous year, these company insiders have bought DiaMedica Therapeutics stock:
  1. Koch Thomas Von (Major Shareholder)
  2. David J Wambeke (Insider)
  3. Randall Michael Giuffre (Director)
  4. Dietrich John Pauls (CEO)
  5. Scott Kellen (CFO)
Learn More investors buying DiaMedica Therapeutics stock.
$2 Trillion Disappears Because of Fed's Secretive New Move
From Stansberry Research   |   Ad
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Click here to see his new research now.